Assessment System for Sarcopenia Based on Ultrasonographic Data

Sarcopenia Clinical Trial

Official title:

An Artificial Intelligence Assessment System for Risk Grading of Sarcopenia Based on Ultrasonographic Multidimensional Data

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06199856
• Other study ID #: XTang-0001
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: December 2028

Study information

• Verified date: January 2024
• Source: West China Hospital
• Contact: Xinyi Tang, Dr.
• Phone: +8615680819215
• Email: tangxinyi1996[@]outlook.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

1. To develop an artificial intelligence assisted diagnostic model for sarcopenia based on ultrasound images; 2. To develop artificial intelligence classification and regression models for auxiliary diagnosis of sarcopenia, patient strength estimation, and other functions based on ultrasound image data.

Description:

Sarcopenia is a syndrome of age-related muscle mass loss and muscle function decrease, which can be comorbid with a variety of diseases and interacts extensively with various disease states to influence disease prognosis. Diseases such as cancer, diabetes, chronic kidney disease, and rheumatoid arthritis can accelerate the process of muscle loss by affecting myogenic cell regeneration, interfering with protein synthesis, increasing protein consumption, and enhancing protein degradation by the ubiquitination pathway, and the decline in motor function will, in turn, further worsen the prognosis of the disease. Despite some regional differences, the prevalence of sarcopenia has been found to exceed 10%. Early identification of the potential risk of sarcopenia and early intervention in the early stages of muscle mass and function impairment is one of the most important steps to improve the quality of life of older adults. Currently, the diagnosis of sarcopenia relies on three features: loss of muscle mass, loss of muscle strength, and loss of physical performance. At present, physicians usually use bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) to determine skeletal muscle mass index SMI to measure muscle mass, grip strength test to measure muscle strength, gait speed or tools such as SPPB scores to assess physical performance. A diagnosis of sarcopenia can be made when a subject experiences a decrease in SMI combined with a decrease in grip strength or a decrease in gait speed. In the field of medical imaging, researchers have been working to explore and validate appropriate imaging tools and markers to diagnose and evaluate sarcopenia. The common methods for deep mining of medical imaging include radiomics and machine learning, usually by analyzing the texture features of muscles at specific sites to quantify muscle function or segmenting skeletal muscles accurately in two dimensions or three dimensions to quantify muscle mass. Compared to computed tomography (CT) or magnetic resonance imaging (MRI), ultrasound is a more accessible and less costly medical imaging technique, especially in low- and middle-income regions. Ultrasound can be used to conveniently scan local muscles and obtain muscle characteristics such as muscle thickness, cross-sectional area, and pennation angle. Our previous studies have demonstrated that SMI in older adults can be accurately estimated by using muscle thickness at four sites together with basic information such as age and body mass index (BMI), and have found in cross-regional validation that the stability of estimates can be maintained across communities with very different ethnic proportions. However, several existing large studies on ultrasound in sarcopenia are currently focusing only on muscle morphological measurements, ignoring the large amount of hidden ultrasound image information. At the same time, the flexibility of the scanning process has led to greater resistance from radiomics or deep learning tools to use the images for artificial intelligence classification than CT or MRI. Fronted with such a dilemma, we attempted to establish an intelligent risk grading system for sarcopenia, based on multidimensional data including basic information such as age and BMI, ultrasound measurements, and original image content, to complete the risk grading of sarcopenia in older adults in a one-stop manner, so as to realize the rapid screening and classification of potential sarcopenia populations for further clinical management.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: December 2028
• Est. primary completion date: December 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 100 Years

Eligibility

Inclusion Criteria:

• > 50 years of age
• Patients with suspected sarcopenia, for example, who needed assistance with walking, rising from a chair, or climbing stairs; recently had a history of falls walking; recent unintentional weight loss

Exclusion Criteria:

• Amputated arm or leg
• Severe oedema (oedema higher than knee level)
• Implantable pacemaker
• Impaired consciousness, poor general health, or other reasons that would prevent the individual from completing the study

Related Conditions & MeSH terms

• Sarcopenia
• Ultrasound

Intervention

Diagnostic Test:
• ultrasound scan
ultrasound scan

Locations

Country	Name	City	State
China	Xinyi Tang	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death		Within 2 years after the initial ultrasound examination
Primary	Diagnosed sarcopenia	Skeletal muscle mass index (SMI)<7 (men) /5.7 (women)kg/m2 (measured by BIA) and gait speed<1m/s or grip strength<28kg (men)/18kg (women)	Within 2 years after the initial ultrasound examination